UGT2B15 and breast cancer: The metabolism of tamoxifen involves other metabolizing enzymes than CYP2D6, such as CYP3A4/5, 2C8/9, SULT1A1, UGT1A8, UGT2B7, and UGT2B15, which might also have an impact on the availability of endoxifen and other metabolites, and therefore contribute for the heterogeneity in breast cancer outcomes.